Please login to the form below

Not currently logged in
Email:
Password:

Arrowhead Therapeutics

This page shows the latest Arrowhead Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen has bolstered its cardiovascular pipeline by licensing two gene silencing therapies developed by Arrowhead Therapeutics in a deal valued at up to $670m. ... RNA interference (RNAi) specialist Arrowhead pockets $56.5m upfront with another $617m in

Latest news

  • Oncology bias in pharma deals

    Through this deal,  Arrowhead is now a fully integrated RNAi therapeutics developer with three primary siRNA formats. ... disease) to Newron Pharmaceuticals, triggered the termination of Biotie Therapeutics' acquisition of Newron.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2012 Pharma deals during December 2012

    cancer. Finally whilst in California it should be mentioned that Shire has closed a $32.8m research and licence agreement with Arrowhead for research of peptide-targeted therapeutics for rare diseases. ... Commercial deals bring an early Christmas to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics